文献速递免疫规划卫生政策与健康促进

德国脑膜炎球菌病的流行病学与经济负担:系统综述

Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
PubMed 文献 · Vaccine · 2022-02-25

该系统综述基于PubMed和EMBASE截至2020年5月的文献及德国法定报告数据,描述德国侵袭性脑膜炎球菌病(IMD)的流行病学与经济负担。纳入36项研究,其中35项报告流行病学负担、3项报告经济负担;自2004年报告发病率下降,目前全国年发病率为0.3例/10万人,总体下降主要归因于MenB,而MenY和MenW病例在低水平上有所增加。

要点

  • 德国目前IMD全国年发病率为0.3例/10万人,自2004年以来呈逐渐下降趋势。
  • 总体下降主要归因于MenB,而MenY和MenW病例在低水平上有所增加。
  • 经济负担和医疗资源使用数据稀缺,高直接和间接成本凸显疾病相关性。

核心结论

  • IMD虽为罕见病,但高直接和间接成本凸显其对患者、照护者及卫生保健系统的重要性。
  • 未来研究应集中于量化脑膜炎球菌病的长期经济负担和间接成本。
  • 整合的IMD监测与分离株特征描述对于为公共卫生政策提供信息仍至关重要。

研究设计与样本

  • 系统综述基于PubMed和EMBASE截至2020年5月的文献,评估所有关于IMD疾病负担和成本的出版物。
  • 此外使用法定报告数据报告德国截至2019年底的IMD年度病例数和发病率。

主要发现

  • 共纳入36项研究,其中35项报告流行病学负担数据,3项报告经济方面数据。
  • 报告的终点类型和IMD发病率结果因报告年份、人群和数据来源不同而差异很大。
  • 大多数数据报告未提供特定血清群信息。
  • 经济负担和医疗资源使用数据稀缺。
  • 基于法定报告数据,自2004年以来观察到报告的IMD病例发病率下降;目前德国全国年发病率为0.3例/10万人,并已逐渐下降;总体下降主要归因于MenB,而MenY和MenW病例是近年来唯一在低水平上有所增加的。

局限性

  • 报告的终点类型和IMD发病率结果因报告年份、人群和数据来源不同而差异很大。
  • 大多数数据报告未提供特定血清群信息。
  • 经济负担和医疗资源使用数据稀缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Invasive meningococcal disease (IMD) is a notifiable disease in Germany and other European countries. Due to the high lethality of the disease and the risk of long-term consequences, IMD prevention is of high public health relevance despite the low number of cases in the population. This study aims to describe key epidemiological and economic parameters of IMD in Germany to support national decision-making processes for implementing enhanced prevention measures. METHODS: Based on a systematic literature review in PubMed and EMBASE, all publications on the burden of disease and costs of IMD published up to May 2020 were evaluated. Additionally, notification data were used to report the annual case numbers and incidence of IMD in Germany until the end of 2019. RESULTS: Thirty-six studies were included, of which 35 reported data on the epidemiological burden of disease and three reported data on economic aspects of IMD. The type of reported endpoints and results on the incidence of IMD differed widely by reporting year, population, and data source used. Most of the data are reported without specific information about a serogroup. Data on the economic burden of disease and healthcare resource use are scarce. Based on mandatory notification data, a decrease in the incidence of notified IMD cases has been observed since 2004. Currently, the nationwide annual incidence in Germany is at 0.3 cases per 100,000 persons and has gradually decreased. While the overall decline is mainly attributable to MenB, cases with MenY and MenW are the only ones that have increased on a low level in recent years. CONCLUSION: While IMD is a rare disease, high direct and indirect costs illustrate the relevance of the disease for patients, caregivers, as well as for the health care system. Future research should concentrate on quantifying the long-term economic burden and indirect costs of meningococcal disease. Integrated IMD surveillance with isolate characterisation remains crucial to inform public health policies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gruhn S, Witte J, Greiner W, et al. Epidemiology and economic burden of meningococcal disease in Germany: A systematic review. Vaccine. 2022. PMID: 35227520. doi:10.1016/j.vaccine.2022.02.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。